Return To The Previous Page
Buy a Package
Number Of Visible Items Remaining : 3 Item

Omalizumab: Evidence for clinical benefits in different disorders

Omalizumab: Evidence for clinical benefits in different disorders
Strong evidence of benefit:*
Moderate-to-severe allergic asthma (patients greater than 6 years of age)
Chronic spontaneous urticaria (patients greater than 12 years of age)
Chronic rhinosinusitis with nasal polyposis (patients greater than 18 years of age)
IgE-mediated food allergy, for protection from systemic allergic reactions, in conjunction with food allergen avoidance (patients ≥1 year of age )
Good evidence of benefit:
Chronic inducible urticaria
Allergic rhinitis
Protection from systemic allergic reactions during aeroallergen, venom, or food immunotherapy
Protection from systemic allergic reactions during drug desensitization
Viral-induced asthma exacerbations
Some evidence of benefit:
Nonallergic asthma
Mast cell activation disorders
Atopic dermatitis
* Disorders for which omalizumab is approved by the US Food and Drug Administration.
Graphic 104454 Version 5.0